Canagliflozin was the first SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [24–27]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.